m+Medelevator.RU
← Поиск публикаций
Frontiers in pharmacology · 2026

Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Qiu Dianya, Gao Zixuan, Zhang Lu, Ma Tianyu, Wei Xin, Zhang Ziyu, Cao Weihua, Li Xinxin, Wang Shiyu, Deng Wen, Zhang Yaqin, Yao Linmei, Wang Shuojie, Jiang Yuyong, Xie Yao, Li Minghui

Аннотация

Drug-induced liver injury (DILI) is an important drug-induced disease in clinical practice, with a complex pathogenesis and challenges in diagnosis and treatment. Glycyrrhizin preparations are a class of hepatoprotective agents derived from the traditional Chinese medicinal plant Glycyrrhiza uralensis, and have shown significant efficacy in the treatment of DILI due to their multi-target and multi-pathway pharmacological effects. Currently, they have been recommended as core therapeutic drugs for DILI in multiple domestic and international guidelines. This review delves into the advanced evidence-based medical evidence for the treatment of DILI with glycyrrhizin preparations and their recommended status in various guidelines. It also systematically expounds the precise treatment strategies of glycyrrhizin preparations based on DILI classification, severity, and special populations, and elaborately analyzes their cutting-edge mechanisms of action such as regulation of the gut-liver axis and epigenetic modifications. It discusses the challenges in clinical application, such as adverse reactions and predictive markers of efficacy, and their optimization solutions, and looks forward to future research directions. This article aims to promote the precise application of glycyrrhizin preparations in the treatment of DILI, providing practical diagnostic and therapeutic references for clinicians.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты